SM
TPST icon

Sabby Management’s Tempest Therapeutics TPST Stock Holding History

Sabby Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed -$1.87M – 368
2015
Q3 		$1.87M Buy
+1
New +$67.3K 0.08% 165
2015
Q2 		– Hold
0
– – – 252

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Sabby Management's TPST Position: Q1 2026 in Review

Sabby Management reduced its Tempest Therapeutics (TPST) stake by 90% in Q1 2026, selling an estimated $388K and leaving 17,856 shares worth $29.3K. The position accounts for 0.07% of the portfolio, ranked #26.

Sabby Management first reported a position in TPST in Q3 2013 and has held it in 20 quarters since. The position peaked at $10.3M in Q2 2015. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.

  • Sabby Management held 17,856 shares of Tempest Therapeutics worth $29.3K as of Q1 2026.
  • Sabby Management sold 160,736 Tempest Therapeutics shares in Q1 2026, an estimated $388K.
  • Tempest Therapeutics made up 0.07% of Sabby Management's portfolio in Q1 2026, its #26 holding.
  • Sabby Management first reported a position in Tempest Therapeutics in Q3 2013 and has held it in 20 quarters since.
  • Sabby Management's Tempest Therapeutics position peaked at $10.3M in Q2 2015.
  • 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.